Effectiveness and toxicity of preoperative therapy in stage iiia non-small cell lung cancer including the memorial sloan-kettering experience with induction mvp in patients with bulky mediastinal lymph node metastases (Clinical n2) Academic Article Article uri icon

Overview

MeSH Major

  • Artifacts
  • Radiography, Thoracic

abstract

  • The use of preoperative chemotherapy with mitomycin, vinblastine and cisplatin (MVP) has led to improved complete resection rates and survival in Stage IIIA non-small cell lung cancer with bulky, ipsilateral, mediastinal lymph node metastases (Clinical N2 disease). The addition of preoperative irradiation has also been explored with results not substantially different from preoperative cisplatin-based chemotherapy alone. While preoperative chemotherapy has been shown to be feasible, the toxicity of both the chemotherapy and the subsequent resection is of concern with an overall treatment-related mortality of nearly 8%. The careful selection of patients, swift management of neutropenia, and meticulous perioperative pulmonary care has the potential to reduce the mortality from multimodality therapy. Having shown survival benefit in multiple single-institution and randomized trials, induction chemotherapy followed by surgery or irradiation is now the treatment of choice for patients with Stage IIIA non-small cell lung cancer with mediastinal lymph node metastases.

publication date

  • January 1995

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/0169-5002(95)00420-6

PubMed ID

  • 7551934

Additional Document Info

start page

  • S47

end page

  • 57

volume

  • 12

number

  • SUPPL. 1